Colon Cancer - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 670
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C10829AE6C0EN
Leaflet:

Download PDF Leaflet

Colon Cancer - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Colon Cancer - Pipeline Review, H2 2015’, provides an overview of the Colon Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Colon Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Colon Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Colon Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Colon Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Colon Cancer Overview
Therapeutics Development
Colon Cancer - Therapeutics under Development by Companies
Colon Cancer - Therapeutics under Investigation by Universities/Institutes
Colon Cancer - Pipeline Products Glance
Colon Cancer - Products under Development by Companies
Colon Cancer - Products under Investigation by Universities/Institutes
Colon Cancer - Companies Involved in Therapeutics Development
Colon Cancer - Therapeutics Assessment
Drug Profiles
Colon Cancer - Recent Pipeline Updates
Colon Cancer - Dormant Projects
Colon Cancer - Discontinued Products
Colon Cancer - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Colon Cancer, H2 2015
Number of Products under Development for Colon Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Development by Companies, H2 2015 (Contd..10)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
Colon Cancer - Pipeline by ACF Pharmaceuticals, LLC, H2 2015
Colon Cancer - Pipeline by Aduro BioTech, Inc., H2 2015
Colon Cancer - Pipeline by Advanced Proteome Therapeutics Corporation, H2 2015
Colon Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2015
Colon Cancer - Pipeline by Agenus, Inc., H2 2015
Colon Cancer - Pipeline by AGV Discovery, SAS, H2 2015
Colon Cancer - Pipeline by AIMM Therapeutics B.V., H2 2015
Colon Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2015
Colon Cancer - Pipeline by Ambrx, Inc., H2 2015
Colon Cancer - Pipeline by Anavex Life Sciences Corp., H2 2015
Colon Cancer - Pipeline by AndroScience Corporation, H2 2015
Colon Cancer - Pipeline by ANP Technologies, Inc., H2 2015
Colon Cancer - Pipeline by Aphios Corporation, H2 2015
Colon Cancer - Pipeline by Aposense Ltd., H2 2015
Colon Cancer - Pipeline by Aptose Biosciences Inc., H2 2015
Colon Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
Colon Cancer - Pipeline by AstraZeneca Plc, H2 2015
Colon Cancer - Pipeline by Aurigene Discovery Technologies Limited, H2 2015
Colon Cancer - Pipeline by Bio-Path Holdings, Inc., H2 2015
Colon Cancer - Pipeline by Biogazelle, H2 2015
Colon Cancer - Pipeline by Bioncotech Therapeutics S.L., H2 2015
Colon Cancer - Pipeline by Caladrius Biosciences, Inc. , H2 2015
Colon Cancer - Pipeline by Can-Fite BioPharma Ltd., H2 2015
Colon Cancer - Pipeline by Carna Biosciences, Inc., H2 2015
Colon Cancer - Pipeline by Celyad SA, H2 2015
Colon Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2015
Colon Cancer - Pipeline by CureFAKtor Pharmaceuticals, LLC, H2 2015
Colon Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015
Colon Cancer - Pipeline by CytomX Therapeutics, Inc., H2 2015
Colon Cancer - Pipeline by Cytune Pharma SAS, H2 2015
Colon Cancer - Pipeline by CZ BioMed Corp, H2 2015
Colon Cancer - Pipeline by DEKK-TEC, Inc., H2 2015
Colon Cancer - Pipeline by Digna Biotech, S.L., H2 2015
Colon Cancer - Pipeline by EntreChem, S.L., H2 2015
Colon Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Colon Cancer - Pipeline by GlycaNova Norway AS, H2 2015
Colon Cancer - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Colon Cancer - Pipeline by Heat Biologics, Inc., H2 2015
Colon Cancer - Pipeline by Helix BioPharma Corp., H2 2015
Colon Cancer - Pipeline by Histogen, Inc., H2 2015
Colon Cancer - Pipeline by Horizon Pharma Plc, H2 2015
Colon Cancer - Pipeline by Huperion Sarl, H2 2015
Colon Cancer - Pipeline by Idera Pharmaceuticals, Inc., H2 2015
Colon Cancer - Pipeline by Ignyta, Inc., H2 2015
Colon Cancer - Pipeline by Immunomedics, Inc., H2 2015
Colon Cancer - Pipeline by Immunotope, Inc., H2 2015
Colon Cancer - Pipeline by IMPACT Therapeutics, Inc., H2 2015
Colon Cancer - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015
Colon Cancer - Pipeline by Inflection Biosciences Limited, H2 2015
Colon Cancer - Pipeline by Innopharmax Inc., H2 2015
Colon Cancer - Pipeline by Intezyne, Inc, H2 2015
Colon Cancer - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2015
Colon Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H2 2015
Colon Cancer - Pipeline by JW Pharmaceutical Corporation, H2 2015
Colon Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Colon Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2015
Colon Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Colon Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2015
Colon Cancer - Pipeline by Lipocure Ltd., H2 2015
Colon Cancer - Pipeline by Lupin Limited, H2 2015
Colon Cancer - Pipeline by Lymphocyte Activation Technologies, S.A., H2 2015
Colon Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2015
Colon Cancer - Pipeline by MacroGenics, Inc., H2 2015
Colon Cancer - Pipeline by Meabco A/S, H2 2015
Colon Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Colon Cancer - Pipeline by Molecular Targeting Technologies, Inc., H2 2015
Colon Cancer - Pipeline by MolMed S.p.A., H2 2015
Colon Cancer - Pipeline by Monopar Therapeutics LLC, H2 2015
Colon Cancer - Pipeline by Multimmune GmbH, H2 2015
Colon Cancer - Pipeline by Novartis AG, H2 2015
Colon Cancer - Pipeline by Omeros Corporation, H2 2015
Colon Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2015
Colon Cancer - Pipeline by Oncology Research International Limited, H2 2015
Colon Cancer - Pipeline by OncoVista Innovative Therapies, Inc., H2 2015
Colon Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Colon Cancer - Pipeline by Orega Biotech SAS, H2 2015
Colon Cancer - Pipeline by OSE Pharma SA, H2 2015
Colon Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H2 2015
Colon Cancer - Pipeline by Panacela Labs, Inc., H2 2015
Colon Cancer - Pipeline by PharmAbcine, Inc., H2 2015
Colon Cancer - Pipeline by PharmaCyte Biotech, Inc., H2 2015
Colon Cancer - Pipeline by Pharminox Limited, H2 2015
Colon Cancer - Pipeline by Philogen S.p.A., H2 2015
Colon Cancer - Pipeline by Phosplatin Therapeutics LLC, H2 2015
Colon Cancer - Pipeline by Pique Therapeutics, H2 2015
Colon Cancer - Pipeline by Plexxikon Inc., H2 2015
Colon Cancer - Pipeline by Provecs Medical GmbH, H2 2015
Colon Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2015
Colon Cancer - Pipeline by Qu Biologics Inc., H2 2015
Colon Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015
Colon Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2015
Colon Cancer - Pipeline by Sareum Holdings Plc, H2 2015
Colon Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H2 2015
Colon Cancer - Pipeline by Sellas Inc., H2 2015
Colon Cancer - Pipeline by Sigma-Tau S.p.A., H2 2015
Colon Cancer - Pipeline by Sirnaomics, Inc., H2 2015
Colon Cancer - Pipeline by Sorrento Therapeutics, Inc., H2 2015
Colon Cancer - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2015
Colon Cancer - Pipeline by Starpharma Holdings Limited, H2 2015
Colon Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015
Colon Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Colon Cancer - Pipeline by Takis S.r.l., H2 2015
Colon Cancer - Pipeline by Tautatis Incorporated, H2 2015
Colon Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Colon Cancer - Pipeline by TheRyte Limited, H2 2015
Colon Cancer - Pipeline by Transgene Biotek Limited, H2 2015
Colon Cancer - Pipeline by TVAX Biomedical, Inc., H2 2015
Colon Cancer - Pipeline by Tyg Oncology Ltd., H2 2015
Colon Cancer - Pipeline by Vaccinogen, Inc., H2 2015
Colon Cancer - Pipeline by Vaximm AG, H2 2015
Colon Cancer - Pipeline by Verlyx Pharma Inc., H2 2015
Colon Cancer - Pipeline by Virocan Therapeutics Private Limited, H2 2015
Colon Cancer - Pipeline by Yakult Honsha Co., Ltd., H2 2015
Colon Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Colon Cancer Therapeutics - Recent Pipeline Updates, H2 2015
Colon Cancer - Dormant Projects, H2 2015
Colon Cancer - Dormant Projects (Contd..1), H2 2015
Colon Cancer - Dormant Projects (Contd..2), H2 2015
Colon Cancer - Dormant Projects (Contd..3), H2 2015
Colon Cancer - Dormant Projects (Contd..4), H2 2015
Colon Cancer - Dormant Projects (Contd..5), H2 2015
Colon Cancer - Dormant Projects (Contd..6), H2 2015
Colon Cancer - Dormant Projects (Contd..7), H2 2015
Colon Cancer - Dormant Projects (Contd..8), H2 2015
Colon Cancer - Dormant Projects (Contd..9), H2 2015
Colon Cancer - Dormant Projects (Contd..10), H2 2015
Colon Cancer - Dormant Projects (Contd..11), H2 2015
Colon Cancer - Dormant Projects (Contd..12), H2 2015
Colon Cancer - Dormant Projects (Contd..13), H2 2015
Colon Cancer - Dormant Projects (Contd..14), H2 2015
Colon Cancer - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Colon Cancer, H2 2015
Number of Products under Development for Colon Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

ACF Pharmaceuticals, LLC
Aduro BioTech, Inc.
Advanced Proteome Therapeutics Corporation
Advenchen Laboratories, LLC
Agenus, Inc.
AGV Discovery, SAS
AIMM Therapeutics B.V.
Alethia Biotherapeutics Inc.
Ambrx, Inc.
Anavex Life Sciences Corp.
AndroScience Corporation
ANP Technologies, Inc.
Aphios Corporation
Aposense Ltd.
Aptose Biosciences Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
Aurigene Discovery Technologies Limited
Bio-Path Holdings, Inc.
Biogazelle
Bioncotech Therapeutics S.L.
Caladrius Biosciences, Inc.
Can-Fite BioPharma Ltd.
Carna Biosciences, Inc.
Celyad SA
Critical Outcome Technologies Inc.
CureFAKtor Pharmaceuticals, LLC
Cyclacel Pharmaceuticals, Inc.
CytomX Therapeutics, Inc.
Cytune Pharma SAS
CZ BioMed Corp
DEKK-TEC, Inc.
Digna Biotech, S.L.
EntreChem, S.L.
F. Hoffmann-La Roche Ltd.
GlycaNova Norway AS
HanAll Biopharma Co., Ltd.
Heat Biologics, Inc.
Helix BioPharma Corp.
Histogen, Inc.
Horizon Pharma Plc
Huperion Sarl
Idera Pharmaceuticals, Inc.
Ignyta, Inc.
Immunomedics, Inc.
Immunotope, Inc.
IMPACT Therapeutics, Inc.
Infinity Pharmaceuticals, Inc.
Inflection Biosciences Limited
Innopharmax Inc.
Intezyne, Inc
Ironwood Pharmaceuticals, Inc.
Jasco Pharmaceuticals, LLC.
JW Pharmaceutical Corporation
Karyopharm Therapeutics, Inc.
Kolltan Pharmaceuticals, Inc.
Kyowa Hakko Kirin Co., Ltd.
Les Laboratoires Servier SAS
Lipocure Ltd.
Lupin Limited
Lymphocyte Activation Technologies, S.A.
MabVax Therapeutics Holdings, Inc.
MacroGenics, Inc.
Meabco A/S
Millennium Pharmaceuticals, Inc.
Molecular Targeting Technologies, Inc.
MolMed S.p.A.
Monopar Therapeutics LLC
Multimmune GmbH
Novartis AG
Omeros Corporation
Omnitura Therapeutics Inc.
Oncology Research International Limited
OncoVista Innovative Therapies, Inc.
Ono Pharmaceutical Co., Ltd.
Orega Biotech SAS
OSE Pharma SA
Panacea Pharmaceuticals, Inc.
Panacela Labs, Inc.
PharmAbcine, Inc.
PharmaCyte Biotech, Inc.
Pharminox Limited
Philogen S.p.A.
Phosplatin Therapeutics LLC
Pique Therapeutics
Plexxikon Inc.
Provecs Medical GmbH
Provectus Biopharmaceuticals, Inc.
Qu Biologics Inc.
Regeneron Pharmaceuticals, Inc.
Rexahn Pharmaceuticals, Inc.
Sareum Holdings Plc
Savoy Pharmaceuticals, Inc.
Sellas Inc.
Sigma-Tau S.p.A.
Sirnaomics, Inc.
Sorrento Therapeutics, Inc.
Sphaera Pharma Pvt. Ltd.
Starpharma Holdings Limited
Synta Pharmaceuticals Corp.
Takeda Pharmaceutical Company Limited
Takis S.r.l.
Tautatis Incorporated
Teva Pharmaceutical Industries Limited
TheRyte Limited
Transgene Biotek Limited
TVAX Biomedical, Inc.
Tyg Oncology Ltd.
Vaccinogen, Inc.
Vaximm AG
Verlyx Pharma Inc.
Virocan Therapeutics Private Limited
Yakult Honsha Co., Ltd.
Zensun (Shanghai) Sci & Tech Co., Ltd.
Skip to top


Colon Carcinoma - Pipeline Review, H1 2014 US$ 1,500.00 Mar, 2014 · 45 pages
Colorectal Cancer - Pipeline Review, 2015 US$ 3,200.00 Oct, 2015 · 258 pages
Rectal Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 107 pages
Ureter Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 103 pages
Head and neck Cancer - Pipeline Review, H1 2016 US$ 2,125.00 Apr, 2016 · 1127 pages

Ask Your Question

Colon Cancer - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: